Global Biosimilar Markets: Europe vs United States

Biosimilars aren’t generics. That’s the first thing to understand. While generics copy simple chemical drugs, biosimilars are complex, living-cell-derived versions of biologic medicines - drugs made from proteins, antibodies, or other biological materials. They’re not exact copies, but they’re designed to work the same way, with no meaningful difference in safety or effectiveness. The difference between Europe and the United States in how they’ve handled biosimilars isn’t just about policy - it’s about timing, culture, and who gets to decide what gets prescribed.

Europe Was First - And It Stayed Ahead

Europe didn’t wait. In 2006, the European Medicines Agency (EMA) approved the first biosimilar ever: Omnitrope, a version of human growth hormone. That wasn’t a fluke. It was the start of a deliberate, science-driven system. The EMA built its approval process around a "totality of evidence" approach. That means: detailed lab tests, animal studies, and a few targeted human trials - not full-scale Phase III trials like new drugs. The message was clear: if the data shows similarity, approve it. No extra hoops.

By 2024, Europe had approved over 100 biosimilars. Germany, France, and the UK led the charge. Hospitals there started using tender systems - bulk bidding for drugs - where biosimilars, often 30% cheaper, won by default. Payers didn’t just accept them; they pushed for them. In countries like Germany, biosimilars for rheumatoid arthritis and inflammatory bowel disease now make up more than 80% of prescriptions. Patients didn’t need convincing. Doctors trusted the science. And because the EMA approved drugs for the whole region, manufacturers didn’t have to reapply in each country. Efficiency. Speed. Scale.

The U.S. Started Late - And Got Stuck

The United States passed the Biologics Price Competition and Innovation Act (BPCIA) in 2009 - three years after Europe got started. But the law came with baggage. It created a legal minefield called the "patent dance." Originator companies - like AbbVie with Humira - used every legal tool to delay biosimilar entry. Lawsuits. Patent extensions. Settlements that blocked competition for years. Even when a biosimilar got FDA approval, it didn’t mean it hit the market. In 2024, the U.S. had 14 approved Humira biosimilars - but only six were actually available. The rest were tied up in court deals.

The FDA also made it harder. For years, to get "interchangeable" status - meaning a pharmacist could swap it for the brand without doctor approval - manufacturers had to run expensive "switching studies." These trials asked: if you switch a patient from the brand to the biosimilar, and then back again, does anything bad happen? Europe never required this. The FDA did. And it stalled progress. By 2024, the U.S. had only approved about 20 biosimilars total - a fraction of Europe’s 100+. Adoption was slowest in complex areas like oncology and autoimmune diseases, where biologics cost $100,000+ per year.

Regulatory Shifts Are Changing the Game

Everything started to change in June 2024. The FDA proposed a major rule change: no more mandatory switching studies for interchangeable designation. That’s huge. It aligned the U.S. with Europe’s model. If a biosimilar is proven to be highly similar, and the manufacturing is consistent, then switching shouldn’t be a safety issue. The FDA admitted it had created an unnecessary barrier. Suddenly, the path to interchangeability became clearer. Companies rushed to file new applications.

The Inflation Reduction Act of 2022 helped too. It closed the Medicare Part D coverage gap - the "donut hole" - which meant patients paid less out of pocket. That made biosimilars more attractive to both patients and insurers. Now, with over 118 biologics set to lose patent protection between 2025 and 2034, the U.S. market has a $232 billion opportunity. Pfizer, Merck, and Samsung Bioepis are investing heavily. And with Humira’s patent cliff finally breaking open, biosimilar sales in the U.S. jumped 40% in 2024 alone.

Market Numbers Tell a Clear Story

In 2024, Europe’s biosimilar market was worth between $13 billion and $14.6 billion, depending on how you count. The U.S. market hit $10.9 billion. But here’s the twist: the U.S. is growing faster. Projections show the U.S. market growing at 18.5% annually through 2033, while Europe grows at 17.3%. That’s because the U.S. is catching up - not starting from scratch. Europe’s market is mature. The U.S. is accelerating.

North America as a whole (mostly the U.S.) is projected to lead the global biosimilar market by 2027, overtaking Europe in revenue. Why? Because the U.S. has bigger, more expensive biologics coming off patent. Humira, Enbrel, Remicade - these drugs generated billions. Replacing them with biosimilars saves billions. Europe’s biggest biosimilars are for growth hormone and insulin - important, but not as high-cost. The U.S. has more to gain.

Manufacturing and Players Differ

Europe still leads in manufacturing. Germany, in particular, is a biosimilar powerhouse. Companies like Sandoz (Novartis) and Fresenius Kabi have built massive production facilities there. The EU’s centralized approval system means once you make it in Germany, you can sell across 27 countries. That’s a huge incentive.

In the U.S., manufacturers are adapting. Pfizer and Merck are building new biosimilar production lines. Samsung Bioepis, originally from South Korea, is now a major supplier to both markets. But the U.S. supply chain is more fragmented. It’s not just about making the drug - it’s about getting it through pharmacy benefit managers, hospital formularies, and private insurers. That’s slower than a single national tender system.

Where Adoption Is Strongest

In Europe, biosimilars dominate in oncology and autoimmune diseases. Rituxan and Avastin biosimilars now make up over 70% of prescriptions in many countries. Insulin biosimilars are widely used too. In the U.S., early adoption happened in supportive care - like filgrastim (Zarxio) for white blood cell stimulation. It’s simpler, cheaper, and less risky. Now, the big shift is happening in monoclonal antibodies. In 2024, the first biosimilars for Keytruda and Opdivo hit the market. These are $200,000-a-year drugs. Their biosimilars could cut costs by 50% or more. That’s the real game-changer.

What’s Next?

Europe isn’t slowing down. It’s now working on biosimilars for next-generation biologics - like bispecific antibodies and cell therapies. The regulatory framework is ready. The U.S. is catching up fast, but it still has hurdles. Physician education is lagging. Some doctors still think biosimilars are "inferior." Pharmacists aren’t always authorized to substitute. Insurance companies still favor brand names.

But the trend is clear: biosimilars are becoming the norm. The U.S. is learning from Europe’s playbook - simpler approval, fewer legal roadblocks, better payer incentives. The FDA’s 2024 rule change was the turning point. Now, the question isn’t whether biosimilars will succeed - it’s how fast they’ll replace the originals.

By 2030, biosimilars could save the U.S. healthcare system over $100 billion. In Europe, that number could hit $150 billion. The difference between the two markets isn’t about science anymore. It’s about systems. Europe built one that worked. The U.S. is finally fixing its own.

Common Misconceptions

Many still think biosimilars are like generics - just cheaper copies. But biologics are made in living cells, not chemicals. Even tiny changes in manufacturing can affect how they work. That’s why biosimilars need more testing than generics - but not as much as new drugs.

Another myth: biosimilars are unsafe. Over 15 years of real-world use in Europe show no increase in adverse events. The FDA and EMA both require the same safety standards. The difference isn’t safety - it’s access.

Some believe the U.S. market is "behind" because of poor science. It’s not. It’s because of legal battles, fragmented payment systems, and outdated regulations. Now that those are changing, the U.S. is moving fast.